ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US
AstraZeneca today announced that it has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus.
Upon completion of the agreement, Perrigo paid AstraZeneca $380 million to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals. The transaction does not include the transfer of any AstraZeneca employees or facilities.
The agreement completes the global divestment of Entocort, following the agreement entered into in July 2015 with Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights to Entocort outside the US. The divestment further emphasises AstraZeneca's strategic focus on three main therapy areas. The transaction does not impact AstraZeneca's financial guidance for 2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries |
|
|
Esra Erkal-Paler |
UK/Global |
+44 20 7604 8030 |
Neil Burrows |
UK/Global |
+44 20 7604 8032 |
Vanessa Rhodes |
UK/Global |
+44 20 7604 8037 |
Karen Birmingham |
UK/Global |
+44 20 7604 8120 |
Jacob Lund |
Sweden |
+46 8 553 260 20 |
Michele Meixell |
US |
+1 302 885 2677 |
Investor Enquiries |
|
|
UK |
|
|
Thomas Kudsk Larsen |
Oncology |
+44 7818 524185 |
Eugenia Litz |
RIA |
+44 7884 735627 |
Nick Stone |
CVMD |
+44 7717 618834 |
Craig Marks |
Finance |
+44 7881 615764 |
Christer Gruvris |
Consensus Forecasts |
+44 7827 836825 |
US |
|
|
Lindsey Trickett |
Oncology, ING |
+1 240 543 7970 |
Mitch Chan |
Oncology |
+1 240 477 3771 |
Dial / Toll-Free |
|
+1 866 381 7277 |
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal
15 December 2015
-ENDS-
